Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has signed an agreement to acquire 100% of Prothya Biosolutions Belgium BV and all its subsidiaries. Prothya is a leading company in plasma-derived medicines, primarily operating in the Netherlands and Belgium. The transaction is expected to close soon, pending regulatory approvals and standard closing conditions. This acquisition supports Intas and Accord’s goal to expand beyond India and establish a global presence in the plasma-derived therapies market.
Health Technology Insights: Meera Atkins, Joins Lyric as Chief Medical Officer
Prothya Biosolutions is headquartered in Amsterdam and Brussels and operates plasma collection centers in Hungary. Employing approximately 1,200 people, it stands as one of Europe’s largest plasma fractionators. The company was formed in 2021 through the merger of Plasma Industries Belgium, formerly linked to the Belgian Red Cross, and Sanquin Plasma Products, which was part of the Sanquin Blood Supply Foundation. Together, these entities bring more than 60 years of experience in plasma collection and product development.
Binish Chudgar, Chairman of Intas and Accord, stated, “We’re excited to expand our plasma business by acquiring Prothya Biosolutions. By combining our plasma processing abilities in India with Prothya’s strengths, we can create a true global plasma platform that provides essential, often overlooked, treatments to patients worldwide.” Since 2015, Intas’s plasma division in India has supplied hospitals with plasma-based products and operates a Gujarat facility with over one million liters of annual processing capacity, which is planned to expand further.
Health Technology Insights: CT-155 Meets Primary Endpoint in Schizophrenia Study
Nir Epstein, CEO of Prothya, commented, “In the past four years, we’ve entered new markets, developed important therapies, built our own plasma collection network in Hungary, and supplied plasma products to some of the top companies in the plasma-derived medicines industry—while strengthening our organization. I’d like to thank our team for their hard work and dedication to our patients. I believe Accord is the right partner to help Prothya and its people grow and expand globally in the future.”
The global market for plasma-derived medicines, especially intravenous immunoglobulin, is currently valued at about $30 billion and is projected to reach $50 billion by 2035. This acquisition will significantly increase Intas’s fractionation capacity and benefit from Accord’s commercial reach across 85 countries. BofA Securities is serving as the exclusive financial advisor to Accord, while Evercore advises Prothya on this transaction.
Health Technology Insights: Physician Disability Insurance: Set for Life Insurance Warns of Mental Health Exclusions
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
